Novavax Inc (NVAX)
9.35
-0.26
(-2.71%)
USD |
NASDAQ |
Nov 01, 16:00
9.42
+0.07
(+0.75%)
After-Hours: 20:00
Novavax Enterprise Value: 616.13M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 616.13M |
| October 31, 2024 | 657.75M |
| October 30, 2024 | 694.58M |
| October 29, 2024 | 731.40M |
| October 28, 2024 | 760.21M |
| October 25, 2024 | 679.37M |
| October 24, 2024 | 707.38M |
| October 23, 2024 | 720.19M |
| October 22, 2024 | 739.40M |
| October 21, 2024 | 742.60M |
| October 18, 2024 | 749.01M |
| October 17, 2024 | 776.22M |
| October 16, 2024 | 744.20M |
| October 15, 2024 | 1.136B |
| October 14, 2024 | 1.140B |
| October 11, 2024 | 1.125B |
| October 10, 2024 | 1.185B |
| October 09, 2024 | 1.149B |
| October 08, 2024 | 1.207B |
| October 07, 2024 | 1.204B |
| October 04, 2024 | 1.298B |
| October 03, 2024 | 1.428B |
| October 02, 2024 | 1.469B |
| October 01, 2024 | 1.092B |
| September 30, 2024 | 1.141B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.248B |
| September 26, 2024 | 1.064B |
| September 25, 2024 | 1.047B |
| September 24, 2024 | 1.247B |
| September 23, 2024 | 1.168B |
| September 20, 2024 | 1.186B |
| September 19, 2024 | 1.124B |
| September 18, 2024 | 1.130B |
| September 17, 2024 | 1.189B |
| September 16, 2024 | 1.232B |
| September 13, 2024 | 1.298B |
| September 12, 2024 | 1.028B |
| September 11, 2024 | 1.087B |
| September 10, 2024 | 1.152B |
| September 09, 2024 | 1.165B |
| September 06, 2024 | 981.14M |
| September 05, 2024 | 1.032B |
| September 04, 2024 | 1.020B |
| September 03, 2024 | 1.148B |
| August 30, 2024 | 1.101B |
| August 29, 2024 | 944.32M |
| August 28, 2024 | 901.10M |
| August 27, 2024 | 904.30M |
| August 26, 2024 | 961.93M |
| August 23, 2024 | 1.039B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-349.18M
Minimum
Mar 23 2023
22.60B
Maximum
Feb 08 2021
4.193B
Average
1.448B
Median
Sep 01 2022
Enterprise Value Benchmarks
| Pfizer Inc | 221.03B |
| Moderna Inc | 12.51B |
| BioCryst Pharmaceuticals Inc | 2.281B |
| Eli Lilly and Co | 805.11B |
| AIM ImmunoTech Inc | 9.109M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 162.38M |
| Revenue (Quarterly) | 415.48M |
| Total Expenses (Quarterly) | 254.49M |
| EPS Diluted (Quarterly) | 0.99 |
| Gross Profit Margin (Quarterly) | 88.87% |
| Profit Margin (Quarterly) | 39.08% |
| Earnings Yield | -29.84% |
| Normalized Earnings Yield | -29.84 |